Likewise, Trimethlyamine-N-oxide (TMAO) level, an OCT2 substrate (13), was found markedly higher in the plasma of patients with chronic kidney disease receiving dialysis than in the plasma of healthy individuals. The gene discussed is SLC22A2; the disease is chronic kidney disease.